Gilead Sciences to Present Pivotal Research at The Liver Meeting® 2024

Gilead Sciences, Inc. (Nasdaq: GILD) announced new research to be presented at The Liver Meeting ® 2024, hosted by the American Association f...

October 23, 2024 | Wednesday | News
Ionis and AstraZeneca's WAINZUA Recommended for EU Approval for Hereditary Amyloidosis Treatment

Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) announced that Ionis' and AstraZeneca's WAINZUA (eplontersen) has been recommended for approval by the Comm...

October 22, 2024 | Tuesday | News
Novartis’ Kisqali Receives Positive CHMP Opinion for Adjuvant Treatment of High-Risk Early Breast Cancer

Novartis announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion and...

October 21, 2024 | Monday | News
Roche's Vabysmo Shows Positive Vision Improvement in Diverse Populations with Diabetic Macular Edema

Roche (SIX: RO, ROG; OTCQX: RHHBY) announced positive topline one-year results from the open-label, single-arm phase IV ELEVATUM study evaluating Vabysmo&r...

October 21, 2024 | Monday | News
Merck Presents Promising Phase 3 Results for CAPVAXIVE™ Vaccine at IDWeek 2024

Merck (NYSE: MRK), known as MSD outside of the United States and Canada, announced results from STRIDE-8, a Phase 3 trial evaluating CAPVAXIVE™ (Pneu...

October 17, 2024 | Thursday | News
Jazz Pharmaceuticals Reports Positive Phase 3 Results for Zepzelca® Combined with Atezolizumab in Small Cell Lung Cancer

Jazz Pharmaceuticals plc (Nasdaq: JAZZ) announced positive top-line results from the Phase 3 clinical trial evaluating Zepzelca® (lurbinected...

October 16, 2024 | Wednesday | News
Exelixis and MSD Announce Strategic Collaboration to Evaluate Zanzalintinib in Combination with KEYTRUDA® and WELIREG® for Advanced Cancers

Exelixis, Inc. (Nasdaq: EXEL) and Merck (NYSE: MRK), known as MSD outside of the United States and Canada, announced that the companies have entered i...

October 15, 2024 | Tuesday | News
Sandoz Launches First FDA-Approved Generic Paclitaxel for Metastatic Breast Cancer

First FDA-approved abbreviated new drug application (ANDA) to reference medicine Single-dose 100 mg vial for intravenous use, approved for metastatic ...

October 14, 2024 | Monday | News
New MammoScreen® AI Enhances Breast Cancer Screening with Comprehensive Workflow Features

New MammoScreen® AI delivers a comprehensive suite of features including breast density and pre-reporting, creating the ultimate ...

October 11, 2024 | Friday | News
Andelyn Biosciences Partners with Hubble Therapeutics to Advance Gene Therapy for Rare Childhood Blindness

 Andelyn Biosciences, Inc., a leading and patient-focused cell and gene therapy Contract Development and Manufacturing Organization (CDMO), has been s...

October 11, 2024 | Friday | News
HBC Immunology Achieves Breakthrough in Prostate Cancer Treatment with Novel Peptide FT-002a

HBC Immunology (HBCI) is pleased to announce the successful completion of its prostate cancer treatment xenograft studies with its lead peptide FT-002a i...

October 09, 2024 | Wednesday | News
Global TB Summit 2024: QIAGEN’s QuantiFERON®-TB Gold Plus Blood Test at the Forefront of Latent TB Detection and Global Disease Control

QIAGEN’s leading tuberculosis blood test QuantiFERON®-TB Gold Plus remains crucial for detection of latent tuberculosis infection, aiding in ...

October 08, 2024 | Tuesday | News
Citryll Launches Pioneering Collaboration with Dutch Rheumatology Experts to Advance NET-Targeting Therapies for Rheumatoid Arthritis

Learnings will be used in the clinical development programs of NET-targeting therapies such as Citryll’s lead anti-inflammatory candidate CIT-013 ...

October 03, 2024 | Thursday | News
LeaderMed and Combiphar Form Joint Venture to Launch Phase 3 Trial of Novel Diabetes Treatment in Indonesia

LeaderMed Group (LeaderMed), a global pharmaceutical development company, and Combiphar, a leading Indonesian pharmaceutical company in Southeast Asia, ann...

October 01, 2024 | Tuesday | News

Survey Box

Poll of the Week

Which area of biopharmaceutical research excites you the most?

× Please select an option to participate in the poll.
Processing...
× You have successfully cast your vote.
 {{ optionDetail.option }}  {{ optionDetail.percentage }}%
 {{ optionDetail.percentage }}% Complete
More polls
Stay Connected

Sign up to our free newsletter and get the latest news sent direct to your inbox

© 2026 Biopharma Boardroom. All Rights Reserved.

Show

Forgot your password?

Show

Show

Lost your password? Please enter your email address. You will receive a link to create a new password.

Back to log-in

Close